Fipamezole

DB06585InvestigationalSmall molecule

Investigated for use/treatment in parkinson's disease and neurologic disorders.

Mechanism: Pharmacologically active on Alpha-2 adrenergic receptors
Curator reviewed
Primary indication: Investigated for use/treatment in parkinson's disease and neurologic disorders.Curator reviewed
Formula / weight: C₁₄H₁₅FN₂ · 230.286 g/mol (avg)
Code names: JP-1730

Resolves to

Compound

Structure

InChIKeyKXSUAWAUCNFBQJ-UHFFFAOYSA-NSMILESCCC1(CC2=CC=C(F)C=C2C1)C1=CNC=N1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Fipamezole, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.